Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ Tue, 22 Nov 2022 14:16:59 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Pharmaceutical drugs – Scuba Dive Talks http://scubadivetalks.com/ 32 32 Cancer Research Horizons and Newcastle University extend their strategic drug discovery alliance with Astex Pharmaceuticals https://scubadivetalks.com/cancer-research-horizons-and-newcastle-university-extend-their-strategic-drug-discovery-alliance-with-astex-pharmaceuticals/ Tue, 22 Nov 2022 13:17:00 +0000 https://scubadivetalks.com/cancer-research-horizons-and-newcastle-university-extend-their-strategic-drug-discovery-alliance-with-astex-pharmaceuticals/ Cancer Research UK’s new innovation engine, Cancer Research Horizons, and Newcastle University, have announced a significant further extension of their strategic drug discovery alliance with Astex Pharmaceuticals (UK) (“Astex”), a of biotechnology dedicated to the discovery and development of new small molecule therapies. The alliance will continue to focus on the discovery of potential new […]]]>

Cancer Research UK’s new innovation engine, Cancer Research Horizons, and Newcastle University, have announced a significant further extension of their strategic drug discovery alliance with Astex Pharmaceuticals (UK) (“Astex”), a of biotechnology dedicated to the discovery and development of new small molecule therapies.

The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, providing an innovative path to the development of more effective cancer drugs.

The agreement signed between the three parties will extend their current alliance for an additional 5 years, which, if completed, will result in an ongoing strategic drug discovery alliance spanning 15 years. Cumulatively, this will be one of Cancer Research UK’s longest running translational collaborations with a relationship spanning nearly 20 years.

Too few promising treatments reach cancer patients fast enough, and many discoveries languish in the translational divide.

Building stronger bridges between academic researchers and industry is key to ensuring there is a pathway for potentially useful compounds to progress to the next stages of drug development and eventually treatments for patients.

The alliance brings together world-leading researchers in structural and cellular biology and medicinal chemistry with Astex’s innovative small-molecule fragment-based drug discovery and development capabilities, to accelerate promising discoveries coming out of the laboratory and enter the clinic. .

The existing alliance portfolio includes several early-stage target validation and outcome identification projects, with projects progressing to more advanced stages of preclinical development.

This multi-project alliance has proven to be a powerful approach for the discovery of innovative drugs. The alliance has already led to the identification of an antagonist compound of MDM2-p53 (ASTX295) which has entered clinical evaluation. This builds on the success of a previous collaboration between Astex, Newcastle and Cancer Research UK on the evaluation of inhibitors of the tyrosine kinase family of the fibroblast growth factor receptor, a key cancer target which ultimately led to the development of a first-class drug.

Under the terms of the alliance agreement, Astex retains the right to an exclusive worldwide license to advance the most promising projects into preclinical and clinical drug development. Cancer Research Horizons and Newcastle University are eligible to receive milestone payments and royalties on all compounds that enter clinical development and enter the market.

The extension of this alliance demonstrates the long-term success of the efforts of the three partners over nearly 20 years of existing collaboration. We are excited to see this alliance continue under our new organization, Cancer Research Horizons, which will provide the scale, agility and access to commercial expertise any partner needs to accelerate promising discoveries outside of the lab. and in the hands of patients. .”

Dr. Iain Foulkes, Executive Director, Cancer Research Horizons

Dr David Rees, Chief Scientific Officer of Astex Pharmaceuticals (UK), said: “Our strategic alliance with Newcastle and CRT is an important and fruitful collaboration for Astex. We are excited to expand our alliance to discover new compounds to advance in development. »

Steve Wedge, Scientific Director of Cancer Research Horizons and Professor of Stratified Discovery of Cancer Medicine at the University of Newcastle, said: “This important university-industry collaboration has been a real success, and I am delighted to see it continue to rely on the impressive track record of all the partners. Risk-sharing partnerships like this allow us to bring together complementary expertise and enable us to maximize the development of our world-class cancer treatment research.

]]>
UPSTO Continues Discussions on Pharmaceutical Patents – Patent https://scubadivetalks.com/upsto-continues-discussions-on-pharmaceutical-patents-patent/ Thu, 17 Nov 2022 02:12:48 +0000 https://scubadivetalks.com/upsto-continues-discussions-on-pharmaceutical-patents-patent/ The USPTO will host a “Public Listening Session” on January 19, 2023, focused on proposed USPTO-FDA collaborative initiatives pursuant to President Biden’s Executive Order on “Advancing Competition in the American Economy” to “promote a better access to medicine for American families”. The listening session will take place days before public comment is expected on the […]]]>

The USPTO will host a “Public Listening Session” on January 19, 2023, focused on proposed USPTO-FDA collaborative initiatives pursuant to President Biden’s Executive Order on “Advancing Competition in the American Economy” to “promote a better access to medicine for American families”. The listening session will take place days before public comment is expected on the USPTO’s “proposed initiatives to enhance the robustness and trustworthiness of patents,” which were issued under the same executive order. .

As I wrote in my article on proposed “robustness and reliability” initiatives, the USPTO is under pressure from Congress to fix perceived problems with pharmaceutical patents. Stakeholders should not miss these opportunities to help the USPTO address Congressional concerns without undermining the strong tradition of promoting innovation and competition of the US patent system.

USPTO-FDA Collaboration Discussion Topics

The Federal Register Notice announcing the public listening session outlines the following possible discussion topics.

1. What publicly available FDA resources should be included when training USPTO patent examiners on the tools they can use to assess the patentability of claimed inventions?

2. What mechanisms could help patent examiners determine whether applicants or patentees have submitted conflicting statements to the USPTO and the FDA? Please explain if there are any privacy issues with these mechanisms and, if so, how these issues might be resolved.

See also the Federal Register Notice of July 29, 2022 on “Duties of Disclosure and Reasonable Inquiry During Examination, Reexamination, and Reissue, and for Proceedings before the Trial and Appeal Board in of patents”.

3. What are the opportunities and challenges of using AIA procedures to address the patentability of claims in pharmaceutical and biotechnology patents, including how these procedures may intersect with the Hatch-Waxman disputes in paragraph IV and Biologics Price Competition and Innovation Act the “patent dance” framework that biosimilar applicants and reference product sponsors use to address any patent infringement concerns?

According USPTO Statisticsin June 2021, only 4% of all AIA trials challenged patents listed in the Orange Book.

4. How can the USPTO and FDA enhance their collaboration and exchange of information in determining whether a patent is eligible for a patent term extension (PTE) and the duration of any extension under 35 USC 156 . ..?

5. The FDA is already publishing PTE applications on www.regulations.govand the USPTO publishes the PTE applications on its Patent Center Portal …. The USPTO also recently provided centralized access to a list of PTE applications filed over the past five years here. …. What additional information would be useful to include on this web page?

The list of PTE applications includes PTE applications filed as recently as August 10, 2022. It will be interesting to see how often it is updated. The list also includes requests that have been granted.

6. What policy considerations or concerns should the USPTO and FDA explore with respect to patent use methods and, if any, associated FDA use codes, including with respect to generic, 505(b)(2) drugs and biosimilar candidates that do not seek approval (i.e., seek to exclude from their labeling) method of use information protected by a patent (sometimes referred to as “skinny labelling”)?

Maybe the USPTO refers to patents like these.

7. What policy considerations or concerns should the USPTO and FDA explore regarding the patenting of risk assessment and mitigation strategies associated with certain FDA-approved products? What other types of patent claims associated with FDA-regulated products raise policy considerations or concerns for the USPTO and FDA to evaluate?

8. Independently or in conjunction with the initiatives set out in the USPTO Letter [to FDA]what other actions could the USPTO and FDA take in collaboration to address concerns about potential misuse of patents to unduly delay competition or to promote greater availability of generic versions of rare drugs that are no longer covered by patents?

9. What additional input on any of the initiatives listed in the USPTO letter (1(a)-1(h)), or any other related suggestions for USPTO-FDA collaboration, should the agencies consider?

According to the Federal Register notice, the USPTO is interested in “comments from a broad group of stakeholders, including, but not limited to, patients and their caregivers, patient advocates, representatives of the regulated industry, including companies that sell brand name drugs, generic drugs and biosimilars, healthcare organizations, payers and insurers, academic institutions, public interest groups and the general public. »

Share your comments

The Federal Register notice outlines the process for requesting to participate in the listening session as a speaker (including submitting remarks in advance), requesting to attend the listening session in person as a member of the public and register to attend the online listening session. The USPTO will also accept written comments on Discussion Topics submitted through the Federal Electronic Rulemaking Portal by February 6, 2023.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

]]>
Asthma Drugs Market Forecast, Trend Analysis to 2028 | Pfizer, Glaxosmithkline, Novartis, Merck, Boehringer Ingelheim, Astrazeneca, Roche, Teva Pharmaceutical, Vectura Group https://scubadivetalks.com/asthma-drugs-market-forecast-trend-analysis-to-2028-pfizer-glaxosmithkline-novartis-merck-boehringer-ingelheim-astrazeneca-roche-teva-pharmaceutical-vectura-group/ Mon, 14 Nov 2022 03:18:10 +0000 https://scubadivetalks.com/asthma-drugs-market-forecast-trend-analysis-to-2028-pfizer-glaxosmithkline-novartis-merck-boehringer-ingelheim-astrazeneca-roche-teva-pharmaceutical-vectura-group/ New Jersey, United States – The global asthma drug market is expected to grow at a significant rate, Market Research Intellect reports. His latest analysis report, titled “Global Asthma Medicine Outlook, Forecast to 2028“. offers a new lens for reading about the global market. Analysts believe that dynamic consumption patterns should possess a good influence […]]]>

New Jersey, United States – The global asthma drug market is expected to grow at a significant rate, Market Research Intellect reports. His latest analysis report, titled “Global Asthma Medicine Outlook, Forecast to 2028“. offers a new lens for reading about the global market. Analysts believe that dynamic consumption patterns should possess a good influence on the market. For a brief summary of asthma medications around the world, the analysis report provides an overview of the associated government. It explains the various factors that form an essential component of the market. It comprises the definition and hence scope of the market with in-depth rationalization of market drivers, opportunities, restraints, and threats.

The major and emerging players of Global Asthma Drug are discussed in detail in the report. The analysts authoring the report have thoroughly studied all aspects of the business of the major players operating within the international Asthma Drugs Market. In the business identification section, the report offers in-depth business identification of all aligned players. The players are studied based on various factors such as market share, growth methods, new product launch, recent developments, future plans, revenue, ratio, sales, capacity, production and the product portfolio.

Get Sample PDF (Including Tables & Figures, Graphs & Graphs) of Asthma Drugs Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=211618

The report endeavors to offer a 360 degree analysis of the Global Asthma Drugs Market based on an in-depth study of current demand and supply trends, important fiscal statistics of major players who maintain in the market and the influence of the latest economic advances on the market. Developments in each geographical region are mapped using authentic historical data to help gauge the future trajectory of the market across the globe. A SWOT analysis is carried out to identify the strengths, weaknesses, opportunities and threats that these companies expect to see during the forecast period.

Key companies:

  • Pfizer
  • Glaxosmithkline
  • Novartis
  • Merck
  • Boehringer Ingelheim
  • Astrazeneca
  • rock
  • Teva pharmaceutical
  • Vectura Group

Segment by types:

  • Quick rescue medications (rescue medications)
  • Medicines for allergy-induced asthma

Segment by applications:

  • allergic asthma
  • Non-allergic asthma

Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=211618

Impact of COVID-19 on the Asthma Drugs Market industry: Coronavirus recession is an economic recession occurring in the global economy in 2020 due to the COVID-19 pandemic. The pandemic could affect three main aspects of the global economy: production, the supply chain, as well as businesses and financial markets. The report offers a comprehensive version of Asthma Drugs Market will include impact of COVID-19 and anticipated changes on future industry outlook, considering political, economic, social, and technological parameters.

Asthma Drugs Market: Regional Analysis Includes:

Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
North America (United States, Mexico and Canada)
South America (Brazil, etc)
The Middle East and Africa (GCC countries and Egypt)

Contents

Global Asthma Drugs Market 2015-2026, with breakdown data of capacity, sales, production, export, import, revenue, price, cost and margin brute

Chapter 1. Presentation of the report

Chapter 2. Market overview

2.1 Presentation of the main companies

2.2 Asthma Drugs Market Concentration

2.3 Six years Compound annual growth rate (CAGR)

chapter 3.Asthma Drugs Market Value Chain

3.1 Upstream

3.2 Downstream

3.3 Porter’s Five Forces Analysis and SWOT Analysis

Chapter 4. Player Profiles

4.1 Company Profiles

4.2 Product presentation

4.3 Production, income (2015-2020)

4.4 SWOT analysis

Chapter 5. Global Asthma Drugs Market Analysis by Regions

5.1 Asthma Drugs Market Status and Outlook (2016-2026)

5.2 Asthma Drugs Market Size and Growth Rate (2016-2026)

5.3 Local asthma medicine market capacity, import, export, local consumption analysis (2015-2026)

Chapter 6. North America Asthma Drugs Market Analysis by Country

Chapter 7. China Asthma Drugs Market Analysis by Country

Chapter 8. Europe Asthma Drugs Market Analysis by Country

Chapter 9. Asia-Pacific Asthma Drugs Market Analysis by Country

Chapter 10. India Asthma Drugs Market Analysis by Country

Chapter 11. Middle East & Africa Asthma Drugs Market Analysis by Country

Chapter 12. South America Asthma Drugs Market Analysis by Country

Chapter 13. Global Asthma Drugs Market Segment By Type

Chapter 14. Global Asthma Drugs Market Segment By Application

Chapter 15. Asthma Drugs Market Forecast by Regions (2020-2026)

Chapter 16. Annex

Browse Full Report or TOC of Asthma Drugs Market @ https://www.marketresearchintellect.com/product/global-asthma-drugs-market-size-and-forcast/

The report includes the following questions:

  • What is the expected growth rate of the global Asthma Drugs market over the forecast period?
  • Which regional segment is estimated to account for a massive share of the global Asthma Drugs market?
  • What are the key driving factors of the Global Asthma Drugs Market?
  • What are the vital challenges faced by the major players in the Global Asthma Drugs Market?
  • What current trends are likely to offer promising growth prospects in the coming years?
  • How is the competitive landscape of the Global Asthma Drugs Market at present?
  • What are the key driving factors of the Global Asthma Drugs Market?
  • How has covid-19 impacted the growth of the?
  • What latest trends are anticipated to offer prospected growth potential in the years to come?

Most Popular Reports:

Global Bill Splitting Application Market Size and Forecast

Global Car Phone Holder Market Size and Forecast

Global Plus Size Women’s Clothing Market Size and Forecast

Malaysia Power Cable Market Size and Forecast

Global pp woven bag market size and forecast

Global Saas Spend Management Software Market Size and Forecast

Global shared mobility market size and forecast

Global Cro Healthcare Contract Research Organization Market Size and Forecast

Generative Design Market Size and Forecast

Ai Machine Learning Operationalization Software Market Size and Forecast

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients across various industries and organizations with the aim of providing functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing & Construction, Chemicals & Materials, Food & Beverage, and more. These reports provide an in-depth study of the market with industry analysis, market value of regions and countries, and industry-relevant trends.

Contact us:
Mr. Steven Fernandes
Market research intelligence
New Jersey (USA)
Tel: +1-650-781-4080
Website: –https://www.marketresearchintellect.com/

]]>
EQRx redesigns ‘radical’ drug pricing plans for first two drugs https://scubadivetalks.com/eqrx-redesigns-radical-drug-pricing-plans-for-first-two-drugs/ Thu, 10 Nov 2022 17:14:49 +0000 https://scubadivetalks.com/eqrx-redesigns-radical-drug-pricing-plans-for-first-two-drugs/ Diving brief: EQRx plans to “adopt market-based pricing” in the United States for two of its investigational drugs, signaling a step back from its goal of bringing brand-name drugs to market at “drastically lower” prices. If approved, both treatments would compete with from AstraZeneca Tagrisso and Pfizer Ibrance. The high profile startup also said it […]]]>

Diving brief:

  • EQRx plans to “adopt market-based pricing” in the United States for two of its investigational drugs, signaling a step back from its goal of bringing brand-name drugs to market at “drastically lower” prices. If approved, both treatments would compete with from AstraZeneca Tagrisso and Pfizer Ibrance.
  • The high profile startup also said it will not seek Food and Drug Administration approval for its lead cancer drug, sugemalimab, as agency officials want the company to complete a second phase 3 trial. before considering an examination, the the company said on Thursday. The drug was discovered and tested primarily in China, which has become a burning issue for the FDA.
  • The announcements represent major strategic setbacks for EQRx, which had sought to take a “rapid follow-up” approach to compete with blockbuster drugs. Shares fell 30% in early trading.

Overview of the dive:

As the United States grapples with rising prescription drug costs, a number of companies have offered solutions based on the market rather than government regulation. Civica Rx, backed by hospital system Intermountain Healthcare and other partners, aims to alleviate critical generic drug shortages, while the state of California hopes to manufacture its own insulin at a lower cost, to name just two examples.

EQRx was part of this trend, but aimed to bring price competition to brand name drugs rather than focusing on older drugs. Unveiled with marquee leaders and $200 million in funding nearly three years ago, EQRx was able to get a quote on the public market through a special purpose acquisition company under an August 2021 deal.

Two of its lead candidates, sugemalimab and aumolertinib, have been licensed by China-based companies, CStone Pharmaceuticals and Hansoh, respectively. Sugemalimab works similarly to checkpoint inhibitors like Keytruda from Merck & Co., while aumolertinib is similar to Tagrisso from AstraZeneca.

This strategy has run into difficulties, however, as the FDA has taken a more critical view of drugs primarily developed and tested in China. Trials conducted in several countries can capture genetic differences as well as medical care practices that might affect how long patients survive or stay in remission after treatment. Earlier this year, the FDA rejected a drug sponsored by Eli Lilly on this problem.

In a statement, EQRx said it sees “no commercially viable route” for sugemalimab in lung cancer in the United States, but is still in discussions with the FDA for a type of lymphoma.

For aumolertinib, the company said a trial in combination with chemotherapy could meet FDA standards. This trial compares the combination to Tagrisso alone and aumolertinib alone, and may have sufficient data to support approval by 2027. In the meantime, the drug has generated data that UK drug regulators have accepted review, and EQRx may pursue further filings overseas.

A third EQRx drug, called lerociclib and discovered by a US-based company, is being tested internationally in metastatic breast cancer. The company intends to start a US-led Phase 3 endometrial trial in 2023. The drug would compete with Pfizer’s Ibrance and Eli Lilly’s Verzenio.

Aumolertinib and lerociclib are the two drugs for which the company plans to adopt market-based pricing. “We are adapting and believe that using a market-based pricing approach for our lead cancer programs, aumolertinib and lerociclib, will ensure that we can still deliver these important medicines to patients,” said EQRx CEO Melanie Nallichéri.

]]>
England’s Medicines Corps recommends life-saving cancer drug https://scubadivetalks.com/englands-medicines-corps-recommends-life-saving-cancer-drug/ Tue, 08 Nov 2022 10:00:58 +0000 https://scubadivetalks.com/englands-medicines-corps-recommends-life-saving-cancer-drug/ A doctor discusses test results with his patient. Getty More patients with a rare form of breast cancer will receive a potentially life-saving cancer drug according to new guidelines released by a health agency in England. Manufactured by MSD, the drug — pembrolizumab — can help shrink “triple negative” tumours. These occur in about 15% […]]]>

More patients with a rare form of breast cancer will receive a potentially life-saving cancer drug according to new guidelines released by a health agency in England.

Manufactured by MSD, the drug — pembrolizumab — can help shrink “triple negative” tumours. These occur in about 15% of breast cancer cases but are difficult to treat, according to the bbc.

Known commercially as Keytruda, the drug is an immunotherapy usually given alongside chemotherapy.

Although it has already been used in the country to prolong the life of women with certain forms of end-stage breast cancer, the recommendation from England’s National Institute for Health and Care Excellence (NICE) means it will be now offered to patients with previous disease.

NICE is a public body that evaluates whether medicines and medical devices offer good value for money. The output of this new direction means the country’s public health body, the National Health Service England, would have to fund the drug for eligible patients.

With a new review underway, pembrolizumab may soon be available for more patients.

Helen Knight, acting director of drug evaluation at NICE, said in a statement: “Triple-negative breast cancer has a relatively poor prognosis and there are few effective treatments compared to other types of the disease.

“Today’s draft guidance means we have now recommended 3 new treatments for routine use in the NHS since June, helping to address this unmet need and giving hope for a longer life. and better to thousands of people.”

Campaigners called the decision “fantastic” and said it would help around 1,600 people with primary triple-negative breast cancer.

Baroness Delyth Morgan, chief executive of Breast Cancer Now, said in a statement: “This a less common but often more aggressive type of breast cancer is more common in women with an inherited BRCA gene, women under age 40, and black women, and the risk of recurrence of triple-negative breast cancer and spread to other parts of the body in the early years after treatment is higher than for other types of breast cancer.

Relatively few options have always been available for these patients, she added. Increased access to pembrolizumab could mean not only that fewer people need invasive surgery and breast removal, but that more could now survive “this devastating disease”, she said. .

“This treatment now needs to be urgently assessed by the Scottish Medicines Consortium so that even more women across the UK have the chance to benefit from it,” she added.

]]>
Toxoplasmosis Drugs Market Recovery and Impact Analysis Report – Glaxo Smithkline Pharmaceuticals Ltd., Turing Pharmaceutical, Snowdon https://scubadivetalks.com/toxoplasmosis-drugs-market-recovery-and-impact-analysis-report-glaxo-smithkline-pharmaceuticals-ltd-turing-pharmaceutical-snowdon/ Sat, 05 Nov 2022 18:48:03 +0000 https://scubadivetalks.com/toxoplasmosis-drugs-market-recovery-and-impact-analysis-report-glaxo-smithkline-pharmaceuticals-ltd-turing-pharmaceutical-snowdon/ Toxoplasmosis Drugs Market research is an intelligence report with meticulous efforts to study the correct and valuable information. The data that has been reviewed takes into account both existing top players and upcoming competitors. The business strategies of key players and new industries entering the market are studied in detail. A well-explained SWOT analysis, revenue […]]]>

Toxoplasmosis Drugs Market research is an intelligence report with meticulous efforts to study the correct and valuable information. The data that has been reviewed takes into account both existing top players and upcoming competitors. The business strategies of key players and new industries entering the market are studied in detail. A well-explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capabilities.

Get sample copy of this report with latest industry trends and impact of COVID-19 @:

https://a2zmarketresearch.com/sample-request

Some of the major companies influencing this market include:

Glaxo Smithkline Pharmaceuticals Ltd., Turing Pharmaceutical, Snowdon, Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Taj Pharmaceuticals Limited.

Various factors are responsible for the growth trajectory of the market, which are studied extensively in the report. In addition, the report lists down the restraints that threaten the global Toxoplasmosis Drugs market. It also assesses the bargaining power of suppliers and buyers, the threat of new entrants and product substitutes, and the degree of competition prevailing in the market. The report also analyzes in detail the influence of the latest government directives. It studies the Toxoplasmosis Drugs market’s trajectory between forecast periods.

Global Toxoplasmosis Drugs Market Research Report Offers:

  • Market definition of the global Toxoplasmosis Drugs market along with the analysis of different influencing factors such as drivers, restraints, and opportunities.
  • In-Depth Research on Global Toxoplasmosis Drugs Competitive Landscape
  • Identification and analysis of micro and macro factors that have and will have an effect on market growth.
  • A comprehensive list of major market players operating in the global Toxoplasmosis Drugs Market.
  • Analysis of various market segments such as type, size, applications and end users.
  • It offers a descriptive analysis of the demand-supply chaining in the global toxoplasmosis drugs market.
  • Statistical analysis of some significant economic facts
  • Figures, tables, graphs, images to clearly describe the market.

Global Toxoplasmosis Drugs Market Segmentation:

Market Segmentation: By Type

Injection
Tablet
Others

Market Segmentation: By Application

Treatment of chronic toxoplasmosis
Treatment of acute toxoplasmosis
Others

Geographical analysis:

The global toxoplasmosis drugs market is split across North America, Europe, Asia-Pacific, Middle East & Africa, and Rest of the World.

Get an exclusive discount on this Premium report:

https://a2zmarketresearch.com/discount

Global cost analysis Toxoplasmosis Drugs Market was carried out taking into account the manufacturing expenses, the cost of labor and raw materials and their rate of market concentration, suppliers and price trends. Other factors such as supply chain, downstream buyers, and sourcing strategy have been assessed to provide a comprehensive and in-depth view of the market. Buyers of the report will also be exposed to market positioning study with factors such as target customer, brand strategy, and pricing strategy taken into consideration.

Key questions answered by the report include:

  • What will be the market size and growth rate by the end of the forecast period?
  • What are the key Toxoplasmosis Drugs market trends impacting the growth of the market?
  • What are the potential growth opportunities and threats faced by the major market competitors?
  • What are the key findings of Porter’s five forces analysis and SWOT analysis of the key players operating in the global Toxoplasmosis Drugs market?
  • This report gives all the information regarding the industry overview, analysis and revenue of this market.
  • What are the market opportunities and threats faced by the vendors in the global Toxoplasmosis Drugs Market?

Table of Contents (TOC)

Global Toxoplasmosis Drugs Market Report 2022 – Growth, Trend and Forecast to 2029

Chapter 1 Toxoplasmosis Drugs Market Overview

Chapter 2 Global Economic Impact on Toxoplasmosis Drugs Industry

Chapter 3 Global Toxoplasmosis Drugs Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region (2014-2020)

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions (2014-2020)

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Toxoplasmosis Drugs Market Forecast (2021-2028)

Chapter 13 Appendix

Buy an exclusive report:

https://www.a2zmarketresearch.com/checkout

Contact us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4157

]]>
New report from Rep. Katie Porter exposes Big Pharma’s introductory price abuse https://scubadivetalks.com/new-report-from-rep-katie-porter-exposes-big-pharmas-introductory-price-abuse/ Wed, 02 Nov 2022 21:38:05 +0000 https://scubadivetalks.com/new-report-from-rep-katie-porter-exposes-big-pharmas-introductory-price-abuse/ WASHINGTON—MP Katie Porter (D-CA) today released a report documenting how Big Pharma priced new drugs ever higher to line its pockets. The report, “Skyrocketing: How Big Pharma Exploits Launch Prices to Cash in on Cancer,” analyzes price and expenditure data to expose how newly launched cancer drug prices put patients and taxpayers at risk. “Our […]]]>

WASHINGTON—MP Katie Porter (D-CA) today released a report documenting how Big Pharma priced new drugs ever higher to line its pockets. The report, “Skyrocketing: How Big Pharma Exploits Launch Prices to Cash in on Cancer,” analyzes price and expenditure data to expose how newly launched cancer drug prices put patients and taxpayers at risk.

“Our report is clear: the prices set by big pharma for new treatments show that these companies view cancer more as a business opportunity than a life-threatening disease,” said Porter, a longtime consumer protection attorney. “For Congress to maximize the Inflation Reduction Act’s protections for patients and taxpayers, we must redouble our efforts to address corporate abuses in drug pricing. Our office’s new report sets a framework for future reforms to address another major driver of high pharmaceutical costs: rising introductory prices for new drugs.”

Read the report: Skyrocketing: How big pharma launches prices to profit from cancer.

Using the example of cancer drugs, MP Porter’s report found that:

  • Introductory prices for cancer drugs are skyrocketing. From 2017 to 2021, the inflation-adjusted average introductory price of self-administered cancer drugs — the types of drugs typically prescribed under Medicare Part D — rose more than 25% to more than 235 $000 per year. When this analysis is expanded to include certain other cancer drugs, such as those given as infusions, the data shows that the average introductory price increased by 53% to $283,000 per year.
  • High introductory prices disproportionately hurt the elderly, the uninsured, and the underinsured. Analyzing Medicare spending data, Congresswoman Porter’s report finds that soaring introductory prices are driving up taxpayer spending on expensive cancer drugs, which cost taxpayers millions of dollars and hurt people in many ways. disproportionate to uninsured, underinsured, or Medicare patients.
  • Addressing soaring introductory drug prices will maximize patient protection and taxpayer savings through the Inflation Reduction Act. Congresswoman Porter’s report shows how the IRA will help patients afford the drugs they need, showing how the law’s out-of-pocket expense cap could save some cancer patients more than $10 $000 a year on expensive drugs. As the Biden administration implements this transformative legislation to protect patients and taxpayers from Big Pharma greed, Porter’s report calls for additional measures to maximize the law’s benefits and address the next frontier of soaring drug prices: introductory prices.

Congresswoman Porter has fought tirelessly to hold Big Pharma accountable on behalf of patients. A version of her proposal holding Big Pharma liable for unreasonable price hikes became law as part of the Inflation Reduction Act. As a member of the supervisory committee, she has facing the CEOs of Big Pharma directly on soaring prescription drug costs. Bring to called for investigations of industry influence on drug approvals, including for high priced drugs placed on the market under the accelerated approval pathway.

Read the full report HERE.

###

]]>
dop: Framework of marketing practices: DoP panel to meet drug pressure groups https://scubadivetalks.com/dop-framework-of-marketing-practices-dop-panel-to-meet-drug-pressure-groups/ Sun, 30 Oct 2022 19:20:51 +0000 https://scubadivetalks.com/dop-framework-of-marketing-practices-dop-panel-to-meet-drug-pressure-groups/ The Department of Pharmaceuticals (DoP) will begin discussions with pharmaceutical lobby groups as it begins to review the regulatory framework on marketing practices in the sector. A high-level committee formed under the leadership of VK Paul de Niti Aayog will meet with representatives of pharmaceutical lobby groups this week to consider the matter. “During the […]]]>
The Department of Pharmaceuticals (DoP) will begin discussions with pharmaceutical lobby groups as it begins to review the regulatory framework on marketing practices in the sector. A high-level committee formed under the leadership of VK Paul de Niti Aayog will meet with representatives of pharmaceutical lobby groups this week to consider the matter.

“During the meeting as part of the stakeholder consultations, the committee wanted to hear the views of the Organization of Pharmaceutical Producers of India (OPPI), the Indian Pharmaceutical Alliance (IPA), the ‘Indian Drug Manufacturers Association (IDMA)’, a published notice reads. by the DoP on the meeting, which will be held on 4 November.

Health Minister Mansukh Mandaviya previously formed the committee after reports that companies were spending exorbitantly on drug promotion.

As reported by ET earlier, the committee is considering legal action if companies are found to be involved in unethical marketing practices. “The committee has looked at existing practice and what is needed to ensure the rules are adhered to,” one person with the knowledge said.

The five-member committee is chaired by Paul, NITI Aayog member, health; it includes S Aparna, Secretary of Pharmaceuticals Department, Health Secretary Rajesh Bhushan and Central Board of Direct Tax (CBDT) Chairman Nitin Gupta as members. N Yuvaraj, Deputy Secretary, Policy, DoP, is Member Secretary.

Advertising and promotion by pharmaceutical companies is currently covered by the Uniform Code of Pharmaceutical Marketing Practice (UCPMP), Indian Medical Council Regulations 2002 and the Central Board of Direct Taxation.

]]>
Collaborative efforts between drugmakers and medical food manufacturers to drive growth opportunities https://scubadivetalks.com/collaborative-efforts-between-drugmakers-and-medical-food-manufacturers-to-drive-growth-opportunities/ Fri, 28 Oct 2022 09:58:00 +0000 https://scubadivetalks.com/collaborative-efforts-between-drugmakers-and-medical-food-manufacturers-to-drive-growth-opportunities/ company logo Dublin, Oct. 28, 2022 (GLOBE NEWSWIRE) — The “Global Medical Food Growth Opportunities” report has been added to from ResearchAndMarkets.com offer. This study aims to understand the role of a medical food in the healing of patients. It provides qualitative and quantitative analysis of medical food ingredients and finished medical food products. North […]]]>

company logo

Dublin, Oct. 28, 2022 (GLOBE NEWSWIRE) — The “Global Medical Food Growth Opportunities” report has been added to from ResearchAndMarkets.com offer.

This study aims to understand the role of a medical food in the healing of patients. It provides qualitative and quantitative analysis of medical food ingredients and finished medical food products.

North America and Europe accounted for the majority of the market share of medical food ingredients and finished medical food products in 2021 owing to growing awareness among physicians and increasing medical adherence among patients. The factors supporting the growth of the market in these regions are the expanding geriatric population, the prevalence of chronic diseases, and the increasing focus by policy makers on the management of malnutrition.

The United States FDA defines a medical food as “a food that is formulated for consumption or enteral administration under the supervision of a physician and is intended for the specific dietary management of a disease or a state for which special nutritional requirements, based on recognized scientific data. principles, are established by medical evaluation.”

Medical foods are interpreted as “foods for special medical purposes (FSMP)” in several countries, including Europe, India, China, Australia and New Zealand. In Japan, medical food is interpreted as “food for the sick”. In Canada, medical foods are governed by the Foods for Special Dietary Use (FSDU) and Infant Foods Regulations.

Globally, the regulatory landscape for medical foods is not clearly defined, even in developed economies. As medical foods are not intended to prevent or treat disease, they are not subject to the same regulatory requirements as pharmaceutical drugs.

By ingredient, the medical food market is split into vitamins and minerals; protein ingredients (animal and vegetable); nutritional lipids; prebiotics; and others (amino acids and probiotics). Among these, protein ingredients held the majority share of 64.0% (2021) in the total medical food ingredients market owing to the significant role they play in healing trauma and disease.

The impact of the COVID-19 pandemic is taken into account in the analysis. The pandemic has brought about both positive and negative changes in the medical food market. Supply chain disruptions due to the closure of processing facilities and other containment measures have affected the sale of ingredients and finished medical foods.

However, the negative effects have been reduced to some extent due to growing consumer awareness and research highlighting the benefits of medical food in patient recovery.

Main characteristics

  • By type, the medical foods market is fragmented into prescription and over-the-counter foods. Prescription medical foods dominated the medical foods market with a share of 60.0% in 2021 due to high demand from developed economies for use in life-threatening health conditions such as oncology health, critical care and trauma, cardiovascular health, diabetes health and cognitive health. Major players in the market, such as Abbott, Nestle Health Science, and Nutricia, offer large portfolios of prescription medical food products to meet growing demand.

  • By mode of administration, the medical nutrition market is categorized into oral tube feeding (food or supplement format) and enteral. Oral mode accounted for the largest market share of 75.0% in 2021. Preference for orally administered products, ease of availability without a prescription, and supportive initiatives are key factors driving the demand for foods orally administered drugs.

  • By application, the medical food market is segmented into malnutrition (including oncology health, immune health, and general malnutrition); metabolic health; digestive health; intensive care and traumatology; diabetes health; cardiovascular health; musculoskeletal health; and cognitive and central nervous system (CNS) health. Malnutrition, metabolic disorders, digestive disorders, intensive care and trauma are the main diseases targeted by medical foods. Brain and cognitive health remains a small segment; nevertheless, it is one of the fastest growing application areas of medical power.

Main topics covered:

1. Strategic imperatives

  • Why is it increasingly difficult to grow taller?

  • The strategic imperative

  • The Impact of the Top 3 Strategic Imperatives on the Medical Food Industry

  • Growth opportunities fuel the growth pipeline engine

2. Analysis of growth opportunities

  • Scope of analysis

  • Medical food – Definition

  • Differences between dietary supplements, medical foods and pharmaceutical drugs

  • Segmentation

  • Definition by type of ingredient

  • Definition by type and mode of administration

  • Definition by application

  • Key competitors

  • Value chain

  • Growth engines

  • Growth constraints

  • Forecast assumptions

  • Impact of the COVID-19 pandemic on the medical food market

  • COVID-19 – Induced Research

  • COVID-19 – Induced market trends

  • Regulatory landscape

  • Insurance Coverage and Reimbursement Scenario

3. Growth Opportunities Analysis – Medical Food Ingredients

  • Growth indicators

  • Role of Ingredients in Patient Recovery – Protein Ingredients

  • Role of Ingredients in Patient Recovery – Nutritional Lipids

  • Role of Ingredients in Patient Recovery – Prebiotics

  • Role of Ingredients in Patient Recovery – Vitamins and Minerals

  • Ingredient Trends

  • Revenue forecast

  • Revenue forecast by ingredient

  • Revenue Forecast Analysis by Ingredients

  • Revenue forecasts by region

  • Revenue forecast analysis by region

  • Competitive environment

  • Competitor Product Matrix

  • Product Launches – Medical Food Ingredients: 2021 and 2022

  • Product Launches – Medical Food Ingredients: 2021

  • Product Launches – Medical Food Ingredients: 2020 and 2022

  • Product Launches – Medical Food Ingredients: 2019 and 2020

4. Growth Opportunity Analysis – Finished Medical Food Products

  • Growth indicators

  • Prescription Medical Foods – Examples

  • Non-Prescription Medical Foods – Examples

  • Role of medical foods in the state of malnutrition

  • Role of Medical Foods in Metabolic Health

  • Role of medical food in digestive health

  • Role of medical food in critical care and trauma

  • Role of medical nutrition in musculoskeletal health

  • Role of medical foods in cognitive and CNS health

  • Role of medical diet in diabetes health

  • Role of medical food in cardiovascular health

  • Revenue forecast

  • Revenue forecast analysis

  • Revenue forecast by type

  • Revenue forecast analysis by type

  • Revenue forecasts by mode of administration

  • Analysis of revenue forecasts by mode of administration

  • Revenue forecasts by region

  • Revenue forecast analysis by region

  • Revenue percentage by application and market penetration

  • Competitive environment

  • Revenue sharing

  • Recent acquisitions – 2019-2022

  • Recent Product Launches – 2019, 2020 and 2021

5. Universe of growth opportunities

  • Growth Opportunity 1: Collaborative Efforts Between Drug Manufacturers and Medical Food Manufacturers

  • Growth Opportunity 2: Promotional Activities and Wide Reimbursement Coverage

  • Growth Opportunity 3: Increased focus of research on the design of specific ingredients for medical food applications

  • Growth Opportunity 4: Innovation in Functional Ingredients

6. Next steps

Companies cited

  • Abbott

  • Nestlé Health Sciences

  • nutricia

For more information on this report, visit https://www.researchandmarkets.com/r/85uwr5

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
]]>
Giving more punch to regenerative medicine and cell and gene therapies https://scubadivetalks.com/giving-more-punch-to-regenerative-medicine-and-cell-and-gene-therapies/ Tue, 25 Oct 2022 19:01:19 +0000 https://scubadivetalks.com/giving-more-punch-to-regenerative-medicine-and-cell-and-gene-therapies/ By Anuj Kalsy Sponsored Content Featured By Tissue and organ repair is a key goal of medicine, and many companies pursue this goal. By 2030, the regenerative medicine market is projected to nearly $38 billion, based on an annual growth rate of more than 15% per year. Much of this growth comes from advances in […]]]>

By Anuj Kalsy

Sponsored Content Featured By

Tissue and organ repair is a key goal of medicine, and many companies pursue this goal. By 2030, the regenerative medicine market is projected to nearly $38 billion, based on an annual growth rate of more than 15% per year. Much of this growth comes from advances in stem cells and the pathways around them.

In February, for example, researchers from the IRCCS Bambino Gesù Children’s Hospital in Rome reported about a Phase III clinical trial to add working copies of an altered gene to hematopoietic stem cells that can be used to treat some people with β-thalassemia who are dependent on transfusions. On August 17, the United States Food & Drug Administration (FDA) approved this treatment, called betibeglogene autotemcel, and described it as the “first cellular gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular transfusions of red blood cells”.

To better understand the rise of this type of research and the applications of human cells for this purpose, we spoke with Anuj Kalsy, scientific director of Precision for Medicine, Biological Sample Solutions Division.

Ready-to-use cells

“Human primary cells have been the key material for the research and production of cell therapies, but these cells have not always been easy to access,” explains Kalsy. “There is therefore an urgent need for suitable alternatives or viable, high-quality cell products, which can be used as powerful research tools by the R&D community in the life science industry.” To explore stem cells and a variety of immune system mechanisms, Precision for Medicine provides scientists with easy access to reliable, well-characterized cells.

For work in cell and gene therapies, stem cells, and regenerative medicine, Precision for Medicine offers a variety of leukopak products, which include specific cell types taken from a patient’s peripheral blood by a special form of apheresis. “Leukapheresis removes leukocytes — white blood cells — and returns the rest of the cells — granulocytes, platelets, and red blood cells — to the human donor,” Kalsy explains. Therefore, a leukopak provides a rich source of white blood cells – an average of around 73% in each leukopak. Of these cells, about 38% are CD8+ T cells and 18% are CD4+ T cells. “T cells have gained popularity in the cell and gene therapy markets due to many life science industry players focusing on the development of CAR-T cell therapies,” says Kalsy.

Precision for Medicine can provide fresh, cryopreserved and mobilized research-grade leucopaks that can be used in basic and clinical research. Mobilized leucopaks are made using FDA-approved granulocyte colony-stimulating factor (G-CSF) drugs, such as 5-day filgrastim, to mobilize and acquire the highest number of CD34+ stem cells.

“Leucopaks are the preferred choice in the life science industry for large-scale research and development efforts, especially early discovery and preclinical efforts, instead of the typical choice of PBMCs or blood mononuclear cells. device,” says Kalsy. “Research studies require consistency from trial to trial and large cell counts.” Leukopaks meet both of these requirements. For example, Kalsy notes that compared to whole blood products, “leukopheresis can provide up to 100 times more cells from the same donor than a blood draw.” Therefore, “leucopaks are gaining popularity in the cell and gene therapy niche, as they are an excellent source of CD4 and CD8 T cells, B cells, and natural killer or NK cells, all of which are used as therapeutic modalities. . to target human diseases,” says Kalsy.

Precision for Medicine continues to expand its line of leucopaks. For example, the company is developing leukopak enriched with CD34+ stem cells using in vivo mobilization procedures. These will be extremely useful to scientists studying the basic biology and potential therapeutic applications of these hematopoietic stem cells.

Selection of the best cells

For a specific project, Precision for Medicine can create custom leucopaks from people with certain HLA types, particular ethnicities, or even a specific disease. “The selection process involves proper screening and a pool of well-qualified human donors, and this is achieved through our professional staff, which consists of veterans trained by the American Red Cross, as well as our infrastructure which uses a modern and reference equipment for treatment. products of the highest quality,” says Kalsy.

Using research-only leucopaks, Precision for Medicine can acquire a customized collection of cells that meet a customer’s needs for cell type, optimal yield, viability and quality. “Our cell subset products are manufactured using industry standard reagents and qualified protocols, along with rigorous quality control analysis in the workflow,” Kalsy explains. “This ensures high product performance in the hands of our customers.”

To meet so many crucial criteria, Precision for Medicine oversees the entire process. “We have an end-to-end chain of custody across the entire workflow, and we collect these leucopaks from our in-house CLIA-certified blood donation and apheresis facility,” Kalsy says. Then the samples are sent directly to Precision for Medicine’s processing labs.

However, collecting the right cells is not enough. “Our leucopaks are prepared from well-characterized donors,” notes Kalsy. “We have a large database of recallable donors with different HLA types, and we collect demographic information, medical history and IRB consent.”

Explore new interests

As noted, many scientists are investigating treatments developed with CAR-T cells, but other immune cells are also gaining traction. One is NK cells, which Precision for Medicine can supply. “NK cell therapies have shown promising results in very early-stage oncology studies around the world,” says Kalsy. “Several companies are using NK cell therapies to enhance ADCC – antibody-dependent cellular cytotoxicity – in hematological and solid tumors.”

NK cell-based therapies could offer valuable benefits. “The manufacturing cost of NK cell therapies is much, much lower than a CAR-T cell therapy,” says Kalsy. “Some people in the research industry call this therapy ‘the rising star of cancer treatment’.”

Precision for Medicine provides the tools scientists need to find even more rising stars in healthcare. “We are always looking to provide innovative solutions to our life science customers,” says Kalsy. “We are constantly expanding the scope of cases and specimen types for all human diseases, including parallel cohorts of non-diseased or at-risk specimens, to provide scientists with one-stop service, from discovery to translation, to truly applying biomarker-driven healthcare.

Learn more about Precision for medicine and his leucopak offerings.

]]>